Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Inv. presentation
Filed Chapter 11
Monthly oper. report
BIOVEST INTERNATIONAL INC (BVTI) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/05/2013 8-K Quarterly results
07/15/2013 8-K Form 8-K - Current report
03/07/2013 8-K Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...
Docs: "Biovest Files Recapitalization Plan to Strengthen Balance Sheet and Advance Commercialization Strategy for BiovaxID™ Cancer Vaccine - Plan proposes to eliminate $44M senior debt and access approx $5.6M in new financing to support seeking global approvals for lymphoma vaccine TAMPA, FL and MINNEAPOLIS, MN – March 7, 2013 – Biovest International, Inc. today reported that the Company has filed a petition for protection under Chapter 11 of the U.S. Bankruptcy Code and a Plan of Reorganization seeking to implement a restructuring of its balance sheet that would eliminate approximately $44 million in senior secured debt held by Laurus/Valens Funds and Corp Real, LLC while also providing up to approximately $5.6 million in new operating funding. Subject to the Plan becoming effective, Biove..."
11/23/2012 8-K Entry into a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an...
10/15/2012 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
08/14/2012 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
Docs: "Consolidation Therapy in Non-Hodgkin's Lymphoma"
06/12/2012 8-K Form 8-K - Current report
06/07/2012 8-K Investor presentation
Docs: "NCI Study Demonstrates Significant Overall Survival and Time-to-Next-Treatment Benefits for BiovaxID ® Cancer Vaccine Following Rituximab-Chemotherapy in Mantle Cell Lymphoma Study",
"POWERPOINT PRESENTATION"
05/31/2012 8-K Investor presentation
Docs: "Biovest Interviewed by OneMedRadio; Discusses Key Milestones Expected to Establish BiovaxID ® as the World's First Personalized Cancer Vaccine for the Treatment of Non-Hodgkin's Lymphoma TAMPA, FL and MINNEAPOLIS, MN - May 31, 2012 - Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that Brett Johnson, President and Executive Editor of OneMedPlace interviewed Biovest's President and CEO, Samuel S. Duffey, and its Senior Vice President, Product Development & Regulatory Affairs, Carlos F. Santos, Ph.D. In the webcast audio interview on OneMedRadio, Biovest discussed its global regulatory strategy for BiovaxID ® , Biovest's personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, including plans to file ...",
"A PowerPoint presentation, portions of which are incorporated in the video presentation of the Biovest Interview by OneMedRadio referenced in attached hereto and which may be used from time to time in presentations to various third parties"
05/14/2012 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Biovest to Seek Marketing Approval in the EU for BiovaxID ® Personalized Lymphoma Cancer Vaccine TAMPA, FL and MINNEAPOLIS, MN - May 14, 2012 - Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that Biovest plans to file for marketing approval in the European Union for BiovaxID ® , its personalized cancer vaccine for the treatment of follicular non-Hodgkin's lymphoma, an incurable cancer of the immune system. Biovest plans to file a Marketing Authorization Application , with the European Medicines Agency , the Agency responsible for the scientific evaluation of applications for the EU under the centralized procedure. EMA approval would establish BiovaxID as the first cancer vaccine available in Europe for lymphoma patients. Bio..."
04/23/2012 8-K Form 8-K - Current report
04/19/2012 8-K Investor presentation
Docs: "Biovest Interviewed by OneMedRadio Regarding Global Regulatory Strategy to Seek Approvals for BiovaxID® Cancer Vaccine",
"A PowerPoint presentation, portions of which are incorporated in the video presentation of the Biovest Interview by OneMedPlace referenced in attached hereto and which may be used from time to time in presentations to various third parties"
04/10/2012 8-K Form 8-K - Current report
04/03/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/08/2012 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "Certificate of Amendment of Amended and Restated Certificate of Incorporation of Biovest International, Inc"
02/01/2012 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "OneMedPlace Initiates Research Coverage on Biovest and BiovaxID® Personalized Lymphoma Vaccine TAMPA, FL and MINNEAPOLIS, MN - February 1, 2012 - Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that OneMedPlace, a biotechnology-focused research and media organization engaged by Biovest, has initiated research coverage on Biovest. The new report, issued this week by Dr. Malini Chatterjee, Ph.D., discusses the anticipated regulatory pathway and market opportunity for BiovaxID®, Biovest's personalized cancer vaccine for the treatment of certain B-cell subtypes of non-Hodgkin's lymphoma . Dr. Chatterjee's report forecasts that, “Over the next several months, BVTI's market position and stock profile could change dramatically as th..."
01/19/2012 8-K Form 8-K - Current report
01/12/2012 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Biovest Collaborates with Max Planck Institute to Advance its Hollow Fiber Bioreactors for the Manufacture of Viral Vaccines TAMPA, FL and MINNEAPOLIS, MN - January 12, 2012 - Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that Biovest has entered into a key Research Agreement with the Max Planck Institute for Dynamics of Complex Technical Systems, part of the Max Planck Society, Germany's most successful research organization with more than 17 Nobel laureates having emerged from the rank of its scientists. As part of the agreement, the Max Planck Institute will conduct a series of influenza virus growth studies designed to establish the advantages of Biovest's proprietary Hollow Fiber Bioreactor Systems for the efficient an..."
11/22/2011 8-K Form 8-K - Current report
10/27/2011 8-K Form 8-K - Current report
10/06/2011 8-K Investor presentation
Docs: "Biovest Reports on Regulatory Strategy for Personalized Cancer Vaccine Targeting Non-Hodgkin's Lymphoma TAMPA, FL and MINNEAPOLIS, MN - October 6, 2011 - Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that it has started the process to conduct clinical pre-filing discussions with various regulatory agencies including Health Canada, the U.S. Food & Drug Administration and the European Medicines Agency . The first agency meeting is confirmed and on the calendar with other meetings expected to follow. The meetings will focus on the Company's plans to seek regulatory approval for BiovaxID ® , Biovest's personalized cancer vaccine initially targeting follicular lymphoma, and will help determine the next steps and requirements in ...",
"PowerPoint presentation to be used from time to time in presentations to various third parties"
10/03/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Biovest to Present on Regulatory Strategy for BiovaxID® Cancer Vaccine at MD Becker Cancer Immunotherapy Conference TAMPA, FL and MINNEAPOLIS, MN - October 3, 2011 - Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that Biovest is scheduled to present at the MD Becker Partners Cancer Immunotherapy Conference at the New York Academy of Medicine on October 6th . The presentation will be webcast with the live and archived versions of the broadcast available at the Media Center on Biovest's corporate website. Biovest's Senior Vice President, Product Development & Regulatory Affairs, Dr. Carlos F. Santos, Ph.D., will present on BiovaxID®, the Company's late-stage personalized cancer vaccine for the treatment of non-Hodgkin's lympho..."
09/29/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Biovest's Personalized Cancer Vaccine Targeting Non-Hodgkin's"
09/19/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Biovest and NHRC to Continue Collaboration with Shared Resources to Extend the Potential of Hollow Fiber Bioreactor Technology for Pandemic Influenza Virus TAMPA, FL and MINNEAPOLIS, MN - September 19, 2011 - Biovest International, Inc. , a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. , today announced that the Naval Health Research Center and Biovest are continuing an ongoing collaboration to study Biovest's hollow fiber technology. The collaboration is being conducted as a shared resource within the NHRC's Respiratory Disease Laboratory in San Diego, California. This research collaboration is evaluating the potential use of Biovest's platform systems for the efficient cell culture production of difficult-to-produce biologics including live viral vaccines, virus-like par..."
09/15/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Biovest to Exhibit at Lymphoma Research Foundation Annual Forum TAMPA, FL and MINNEAPOLIS, MN - September 15, 2011 - Biovest International, Inc. today announced that the Company is scheduled to exhibit at the Lymphoma Research Foundation's 16 th Annual North American Educational Forum on Lymphoma at the Brooklyn Marriott Hotel in New York, September 30 - October 2, 2011. “Biovest highly supports the LRF's mission to eradicate lymphoma and to serve those touched by this disease,” stated Samuel S. Duffey, Biovest's President. “Our commitment to deliver a personalized idiotype vaccine to treat lymphoma is driven by our deep concern for lymphoma patients and their families. We strongly believe that ultimately, each patient's immune system holds the key to effectively controlling this disease, ..."
07/07/2011 8-K Form 8-K - Current report
06/15/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Advantages of Biovest's Bio-manufacturing Systems for Viral Cell Production"
06/01/2011 8-K Form 8-K - Current report
05/11/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Biovest Reports New BiovaxID ® Cancer Vaccine Manufacturing Site Has Been Completed at its Minnesota Cell Culture Center"
03/15/2011 8-K Form 8-K - Current report
03/07/2011 8-K Form 8-K - Current report
02/17/2011 8-K Form 8-K - Current report
02/15/2011 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "License Agreement effective September 17, 2004 between Biovest International, Inc. and the Board of Trustees of the Leland Stanford Junior University"
01/21/2011 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy